SPRAVATO® is the only FDA-approved treatment used as monotherapy or in conjunction with an oral antidepressant for adults with treatment-resistant depression (MDD with inadequate response to at least 2 oral antidepressants of adequate dose and duration)

SPRAVATO® is a unique treatment approach that delivers:

Results as early as 24 hours and out to 28 days

Long-term safety and efficacy out to 5 years

A winding mountain road with cars, surrounded by rocky terrain and lush green trees, overlooking a river with boats and a bridge, under a sunset sky.

Spravato offers hope to those with treatment-resistant depression (TRD) who have not found relief from conventional therapies and medications. Typically taken with an oral antidepressant, Spravato can produce long-lasting results in just a few weeks.

Spravato is based on ketamine, an anesthetic that can lead to a diminished or absent sense of pain. It boosts glutamate neurotransmitters to create and strengthen brain pathways to uplift mood and improve overall well-being.